{"id":2396,"date":"2023-04-04T14:31:29","date_gmt":"2023-04-04T14:31:29","guid":{"rendered":"https:\/\/blog.trive.com\/?p=2396"},"modified":"2023-04-04T14:31:30","modified_gmt":"2023-04-04T14:31:30","slug":"reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come","status":"publish","type":"post","link":"https:\/\/blog.trive.com\/de\/investition\/reata-pharmaceuticals-erfolgreiche-bilanz-und-14644-kursgewinn\/","title":{"rendered":"Reata Pharmaceuticals: Erfolgreiche Bilanz und 146,44 % Kursgewinn"},"content":{"rendered":"<p>Reata Pharmaceuticals Inc. (NASDAQ: RETA) hat stark in die eigene Forschungs- und\nEntwicklungsarbeit investiert. In den letzten f\u00fcnf Jahren sind die Forschungs- und\nEntwicklungskosten um 11 % auf 169,84 Mio. USD gestiegen und machten 60 % der Ausgaben aus. Trotz der erheblichen Kosten, die das Endergebnis belasten, ist der Aktienkurs von Reata seit Jahresbeginn um 146,44 % gestiegen. Dies ist auf den Optimismus zur\u00fcckzuf\u00fchren, der in Bezug auf die zuletzt zugelassenen, bisher einmaligen pharmazeutischen Produkte von Reata herrscht.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" loading=\"lazy\" width=\"831\" height=\"435\" src=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta1.png\" alt=\"\" class=\"wp-image-2397\" srcset=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta1.png 831w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta1-300x157.png 300w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta1-768x402.png 768w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta1-18x9.png 18w\" sizes=\"(max-width: 831px) 100vw, 831px\" \/><\/figure>\n\n\n\n<p>Der Aktienkurs von Reata hat sich in den letzten f\u00fcnf Jahren in der Regel besser entwickelt als der NASDAQ100, mit Ausnahme des letzten Jahres, als h\u00f6here Kreditkosten die Aktienbewertungen stark dr\u00fcckten. Der Aktienkurs von Reata reagierte negativ auf das h\u00f6here Zinsumfeld, nachdem die Gesamtverschuldung zwischen 2021 und 2022 um 2.154 % gestiegen war, was zu einem Anstieg der Zinsausgaben um 13 % im gleichen Zeitraum f\u00fchrte.\u00a0\u00a0\u00a0<\/p>\n\n\n\n<h2>Technische Analyse<\/h2>\n\n\n\n<p>Der Aktienkurs von Reata befindet sich in einem steilen Abw\u00e4rtstrend, der durch eine fallende\nKanalstruktur gekennzeichnet ist. Unterst\u00fctzung und Widerstand wurden bei 19,17 USD bzw. 115,17 USD pro Aktie definiert. Der Abw\u00e4rtstrend kam zum Stillstand, als die Ums\u00e4tze zur\u00fcckgingen und der Aktienkurs innerhalb eines Rechteckmusters seitw\u00e4rts konsolidierte. Innerhalb eines Jahres schwankte der Kurs zwischen 19,17 USD und 41,58 USD pro Aktie.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Ein Ausbruch \u00fcber die Marke von 41,58 USD pro Aktie bei hohen Ums\u00e4tzen k\u00f6nnte darauf hindeuten,\ndass bullische Investoren den Kurs nach oben treiben wollen, da der Kampf zwischen ihnen und den B\u00e4ren mit den Bullen auf der Gewinnerseite endete. Wenn der Aufw\u00e4rtstrend anh\u00e4lt, werden die\nBullen wahrscheinlich die n\u00e4chste wichtige Marke von 115,17 USD pro Aktie ins Visier nehmen, was Raum f\u00fcr einen Kursanstieg von 22,71 % l\u00e4sst.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Sollten jedoch die b\u00e4rischen Investoren die Arbeit der Bullen zunichte machen, wird der Aktienkurs\nwahrscheinlich einen R\u00fcckschlag erleiden. Die Bullen werden wahrscheinlich das Niveau des 61,80 %\nFibonacci Retracement Golden Ratio bei 41,48 USD als verlockenden Abschlag zum Kauf der Aktie sehen, wenn sie nicht an der Bewegung teilgenommen haben, die zum Ende des Konsolidierungsmusters f\u00fchrte. Sollte das Golden Ratio als Unterst\u00fctzung jedoch nicht halten, k\u00f6nnte der Kurs um 100 % fallen, so dass 19,17 USD der n\u00e4chste wahrscheinliche Wert f\u00fcr bullische Investoren w\u00e4re.\u00a0\u00a0<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" loading=\"lazy\" width=\"837\" height=\"427\" src=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta2.png\" alt=\"\" class=\"wp-image-2398\" srcset=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta2.png 837w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta2-300x153.png 300w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta2-768x392.png 768w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta2-18x9.png 18w\" sizes=\"(max-width: 837px) 100vw, 837px\" \/><\/figure>\n\n\n\n<h2><strong>Fundamentalanalyse<\/strong>\u00a0<\/h2>\n\n\n\n<p>Aus finanzieller Sicht hat sich Reata mit einem Umsatzr\u00fcckgang von 80,71 % auf 2,22 Mio. USD\nnegativ entwickelt. Trotz des starken Umsatzr\u00fcckgangs blieb der Bruttogewinn mit 1,09 Mio. USD im positiven Bereich. Unter dem Strich blieb jedoch ein geringer Verlust von 311,90 Mio. USD, was einem Anstieg von 4,88 % gegen\u00fcbr dem Vorjahr entspricht.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Der Aktienkurs von Reata hat sich trotz der schlechten Finanzlage nicht verschlechtert, sondern ist\naufgrund der Fortschritte in der Produktentwicklung stabil bis positiv geblieben. Aufgrund der\nZulassung von Skyclarys, einem Medikament zur Behandlung einer seltenen neurologischen Erkrankung, stieg der Aktienkurs um 146,44 %. Analysten gehen davon aus, dass Reata mit Skyclarys einen Umsatz von 1,2 Mrd. USD erzielen wird. Die Bewertung des Pharmagesch\u00e4fts wird sich wahrscheinlich nach Norden bewegen, sobald Einnahmen aus neuen Produkten erzielt werden.&nbsp;<\/p>\n\n\n\n<p>Nach Diskontierung der zuk\u00fcnftigen Cashflows wurde ein fairer Wert von 102,68 USD ermittelt, der wahrscheinlich ist, wenn Reata mit seinen neuesten Produkten erfolgreich Umsatzwachstum erzielt. Da der aktuelle Aktienkurs unterbewertet ist, hat die Aktie ein Aufw\u00e4rtspotenzial von 10,47 % \u00fcber\ndem fairen Wert.\u00a0\u00a0<\/p>\n\n\n\n<h2>Zusammenfassung<\/h2>\n\n\n\n<p>Aus fundamentaler Sicht ist die Performance von Reata eher entmutigend, vor allem f\u00fcr Investoren,\ndie sich von den Gewinnen und Dividendenzahlungen leiten lassen. Da sich das Unternehmen jedoch verpflichtet hat, in Forschung und Entwicklung zu investieren, k\u00f6nnten neue Produktlinien entwickelt, eingef\u00fchrt und in die Ertragsmatrix aufgenommen werden. Investoren, die bullisch eingestellt sind, werden wahrscheinlich in einer besseren Position sein, wenn sie entweder bei 41,48 USD oder 19,17 USD pro Aktie kaufen.&nbsp;&nbsp;&nbsp;<\/p>\n\n\n\n<p><em>Quellen: Reata Pharmaceuticals Inc, TradingView, Koyfin\u00a0<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>Reata Pharmaceuticals Inc (NASDAQ: RETA) has invested heavily in its research and development exercise. Over the past five years, Research and development costs have surged 11% on a compounded annual growth rate basis to $169.84M, making up 60% of the expenses. Despite significant costs weighing on the bottom line, RETA\u2019s share price has surged 146.44% [&hellip;]<\/p>","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.10 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Reata Pharmaceuticals Inc\u2019s Share Price Surges 146.44%. Is there More Growth to Come?<\/title>\n<meta name=\"description\" content=\"Reata Pharmaceuticals Inc (NASDAQ: RETA) has invested heavily in its research and development exercise.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blog.trive.com\/de\/investition\/reata-pharmaceuticals-erfolgreiche-bilanz-und-14644-kursgewinn\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Reata Pharmaceuticals Inc\u2019s Share Price Surges 146.44%. Is there More Growth to Come?\" \/>\n<meta property=\"og:description\" content=\"Reata Pharmaceuticals Inc (NASDAQ: RETA) has invested heavily in its research and development exercise.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blog.trive.com\/de\/investition\/reata-pharmaceuticals-erfolgreiche-bilanz-und-14644-kursgewinn\/\" \/>\n<meta property=\"og:site_name\" content=\"Trive Blog\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-04T14:31:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-04T14:31:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"831\" \/>\n\t<meta property=\"og:image:height\" content=\"435\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Reata Pharmaceuticals Inc\u2019s Share Price Surges 146.44%. Is there More Growth to Come?\" \/>\n<meta name=\"twitter:description\" content=\"Reata Pharmaceuticals Inc (NASDAQ: RETA) has invested heavily in its research and development exercise.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta1.png\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Reata Pharmaceuticals Inc\u2019s Share Price Surges 146.44%. Is there More Growth to Come?\",\"datePublished\":\"2023-04-04T14:31:29+00:00\",\"dateModified\":\"2023-04-04T14:31:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/\"},\"wordCount\":597,\"publisher\":{\"@id\":\"https:\/\/blog.trive.com\/#organization\"},\"articleSection\":[\"Investment\"],\"inLanguage\":\"de-DE\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/\",\"url\":\"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/\",\"name\":\"Reata Pharmaceuticals Inc\u2019s Share Price Surges 146.44%. Is there More Growth to Come?\",\"isPartOf\":{\"@id\":\"https:\/\/blog.trive.com\/#website\"},\"datePublished\":\"2023-04-04T14:31:29+00:00\",\"dateModified\":\"2023-04-04T14:31:30+00:00\",\"description\":\"Reata Pharmaceuticals Inc (NASDAQ: RETA) has invested heavily in its research and development exercise.\",\"breadcrumb\":{\"@id\":\"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/#breadcrumb\"},\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/blog.trive.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Reata Pharmaceuticals Inc\u2019s Share Price Surges 146.44%. Is there More Growth to Come?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/blog.trive.com\/#website\",\"url\":\"https:\/\/blog.trive.com\/\",\"name\":\"Trive Blog\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/blog.trive.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/blog.trive.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"de-DE\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/blog.trive.com\/#organization\",\"name\":\"Trive Blog\",\"url\":\"https:\/\/blog.trive.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png\",\"contentUrl\":\"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png\",\"width\":723,\"height\":199,\"caption\":\"Trive Blog\"},\"image\":{\"@id\":\"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\",\"url\":\"https:\/\/blog.trive.com\/de\/author\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Reata Pharmaceuticals Inc\u2019s Share Price Surges 146.44%. Is there More Growth to Come?","description":"Reata Pharmaceuticals Inc (NASDAQ: RETA) has invested heavily in its research and development exercise.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blog.trive.com\/de\/investition\/reata-pharmaceuticals-erfolgreiche-bilanz-und-14644-kursgewinn\/","og_locale":"de_DE","og_type":"article","og_title":"Reata Pharmaceuticals Inc\u2019s Share Price Surges 146.44%. Is there More Growth to Come?","og_description":"Reata Pharmaceuticals Inc (NASDAQ: RETA) has invested heavily in its research and development exercise.","og_url":"https:\/\/blog.trive.com\/de\/investition\/reata-pharmaceuticals-erfolgreiche-bilanz-und-14644-kursgewinn\/","og_site_name":"Trive Blog","article_published_time":"2023-04-04T14:31:29+00:00","article_modified_time":"2023-04-04T14:31:30+00:00","og_image":[{"width":831,"height":435,"url":"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta1.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_title":"Reata Pharmaceuticals Inc\u2019s Share Price Surges 146.44%. Is there More Growth to Come?","twitter_description":"Reata Pharmaceuticals Inc (NASDAQ: RETA) has invested heavily in its research and development exercise.","twitter_image":"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/04\/040423_Reta1.png","twitter_misc":{"Verfasst von":"","Gesch\u00e4tzte Lesezeit":"4 Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/#article","isPartOf":{"@id":"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/"},"author":{"name":"","@id":""},"headline":"Reata Pharmaceuticals Inc\u2019s Share Price Surges 146.44%. Is there More Growth to Come?","datePublished":"2023-04-04T14:31:29+00:00","dateModified":"2023-04-04T14:31:30+00:00","mainEntityOfPage":{"@id":"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/"},"wordCount":597,"publisher":{"@id":"https:\/\/blog.trive.com\/#organization"},"articleSection":["Investment"],"inLanguage":"de-DE"},{"@type":"WebPage","@id":"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/","url":"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/","name":"Reata Pharmaceuticals Inc\u2019s Share Price Surges 146.44%. Is there More Growth to Come?","isPartOf":{"@id":"https:\/\/blog.trive.com\/#website"},"datePublished":"2023-04-04T14:31:29+00:00","dateModified":"2023-04-04T14:31:30+00:00","description":"Reata Pharmaceuticals Inc (NASDAQ: RETA) has invested heavily in its research and development exercise.","breadcrumb":{"@id":"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/#breadcrumb"},"inLanguage":"de-DE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blog.trive.com\/investment\/reata-pharmaceuticals-incs-share-price-surges-146-44-is-there-more-growth-to-come\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blog.trive.com\/"},{"@type":"ListItem","position":2,"name":"Reata Pharmaceuticals Inc\u2019s Share Price Surges 146.44%. Is there More Growth to Come?"}]},{"@type":"WebSite","@id":"https:\/\/blog.trive.com\/#website","url":"https:\/\/blog.trive.com\/","name":"Trive Blog","description":"","publisher":{"@id":"https:\/\/blog.trive.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blog.trive.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"de-DE"},{"@type":"Organization","@id":"https:\/\/blog.trive.com\/#organization","name":"Trive Blog","url":"https:\/\/blog.trive.com\/","logo":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/","url":"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png","contentUrl":"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png","width":723,"height":199,"caption":"Trive Blog"},"image":{"@id":"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"","url":"https:\/\/blog.trive.com\/de\/author\/"}]}},"_links":{"self":[{"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/posts\/2396"}],"collection":[{"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/comments?post=2396"}],"version-history":[{"count":1,"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/posts\/2396\/revisions"}],"predecessor-version":[{"id":2399,"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/posts\/2396\/revisions\/2399"}],"wp:attachment":[{"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/media?parent=2396"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/categories?post=2396"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/tags?post=2396"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}